Lynn Bowen
About Lynn Bowen
Lynn Bowen is the Vice President of Regulatory Affairs, Advertising Promotion & Labeling at Alkermes, with over two decades of experience in regulatory affairs.
Current Role at Alkermes
Lynn Bowen serves as the Vice President of Regulatory Affairs, Advertising Promotion & Labeling at Alkermes. In this capacity, Lynn is responsible for overseeing all aspects of regulatory compliance related to advertising, promotion, and product labeling. This role involves ensuring that the company's communications align with both regulatory standards and corporate policies.
Previous Experience at Vertex Pharmaceuticals
Before joining Alkermes, Lynn Bowen worked at Vertex Pharmaceuticals. Initially, Lynn served as the Director of Commercial Regulatory Affairs for five years, from 2015 to 2020. In 2020, Lynn was promoted to Senior Director of Commercial Regulatory Affairs, a position held until 2022. These roles involved significant responsibility in managing regulatory oversight for commercial activities.
Role at Bayer HealthCare
Lynn Bowen gained valuable experience at Bayer HealthCare, where Lynn served as Associate Director of Global Regulatory Affairs from 2012 to 2015. During this tenure in Whippany, NJ, Lynn contributed to the company's global regulatory strategies, ensuring compliance across various markets.
Educational Background
Lynn Bowen holds a PhD from Boston University School of Medicine, achieved after seven years of study from 2000 to 2007. Additionally, Lynn earned a Bachelor of Science degree from the Rochester Institute of Technology, completed over four years from 1994 to 1998. This robust educational foundation has underpinned Lynn’s extensive career in regulatory affairs.
Early Career in Research
Lynn Bowen started a career in research as a Research Associate II at the New England Regional Primate Research Center, affiliated with Harvard Medical School, in Southborough, MA, from 1998 to 2000. Following this, Lynn worked as a Graduate Research Assistant at Boston University School of Medicine from 2000 to 2007. These roles provided significant foundational experience in biomedical research.